Description:Erastin is a small molecule identified as a selective inducer of ferroptosis, a form of regulated cell death characterized by the accumulation of lipid peroxides. It is primarily studied for its potential therapeutic applications in cancer treatment, particularly in tumors that are resistant to conventional therapies. The compound functions by inhibiting the cystine/glutamate antiporter system Xc-, leading to decreased levels of intracellular cysteine and glutathione, which are crucial for cellular antioxidant defense. This results in increased oxidative stress and ultimately triggers ferroptotic cell death. Erastin has been shown to selectively target cancer cells while sparing normal cells, making it a promising candidate for further research in oncology. Additionally, its mechanism of action highlights the importance of metabolic pathways in cancer biology, providing insights into potential combination therapies that could enhance treatment efficacy. As research continues, understanding the full spectrum of Erastin's biological effects and its interactions with other cellular pathways will be essential for its development as a therapeutic agent.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
